UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspio.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/672,556	09/25/2003	Dennis M. DiVenuta	9392-2	8847
20792 7590 11/05/2008 MYERS BIGEL SIBLEY & SAJOVEC PO BOX 37428			EXAMINER	
			GAUTHIER, GERALD	
RALEIGH, NC 27627			ART UNIT	PAPER NUMBER
			2614	
			MAIL DATE	DELIVERY MODE
			11/05/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
		10/672,556	DIVENUTA ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Gerald Gauthier	2614			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	correspondence address			
A SH WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DAIS nisons of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tinwill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
2a)□	Responsive to communication(s) filed on <u>11 Sec</u> This action is FINAL . 2b) This Since this application is in condition for alloward closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposit	ion of Claims					
5)⊠ 6)⊠ 7)⊠	 4) Claim(s) 1-111 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) 50,79,97-101 and 109-111 is/are allowed. 6) Claim(s) 1-46,48,51,52,57-64-75,77,80,81,85-96 and 102-108 is/are rejected. 7) Claim(s) 47,49,53-56,76,78 and 82-84 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 					
Applicat	ion Papers					
10)	The specification is objected to by the Examiner The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction The oath or declaration is objected to by the Example 1.	epted or b) objected to by the I drawing(s) be held in abeyance. See ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority (under 35 U.S.C. § 119					
12)□ a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau See the attached detailed Office action for a list of	s have been received. s have been received in Applicati ity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage			
2) Notice 3) Infor	te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) ter No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate			

Art Unit: 2614

DETAILED ACTION

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. Claims 20 and 60 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Claims 20 and 60 are single step claims therefore fails to comply with the enablement requirement. MPEP 2164.08 (a).

Claims 21-29, 31-39, 61-64 and 66-73 are rejected under 35 U.S.C. 112, first paragraph because they are dependent of claims 20 and 60 above.

Claim Rejections - 35 USC § 101

3. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 60 and 65 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. "The computer-readable program code" is a software and is not patentable.

Art Unit: 2614

Claims 61-64, 66-73, 102-106 are rejected under 35 U.S.C. 101 because they are dependent of claims 60 and 65 above.

Claims 1-39 and 87-96 under 35 U.S.C. 101 because they are method claims run by the software claims 60 and 65 above.

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 5. Claims 1-6, 8, 11, 12, 17-26, 28, 31, 32, 36-46, 48, 51, 52, 57-61, 63, 66, 67, 71-75, 77, 80, 81, 85 and 86 are rejected under 35 U.S.C. 102(e) as being anticipated by Garcia (US 6,680,999 B1).

Regarding **claims 1, 20, 40, 60 and 74**, Garcia discloses a method for processing prescriptions [column 1, lines 12-14] comprising:

answering a telephone call from a caller [At step 210, an incoming audio communication is received. The audio communication may come in a telephone call via a telecommunications network 354, column 3, lines 28-43];

accepting identification of a pharmaceutical prescription from the caller [if system 300 has a single pharmacy database, then a prescription number would be sufficient to uniquely identify a patient, column 3, lines 28-43];

querying at least one database using predefined criteria based on the identification of a pharmaceutical prescription to identify a targeted message [if system 300 has a single pharmacy database, then a prescription number would be sufficient to uniquely identify a patient, column 4, lines 3-11]; and

playing the targeted message to the caller [The system 300 provides an output to the caller which is representative of the requested portion of information, column 4, lines 3-11].

Regarding **claims 2, 21, 41, 51, 61 and 75**, Garcia discloses a method wherein the playing is followed by executing a refill call flow for the pharmaceutical prescription [column 3, lines 28-43].

Regarding **claims 3, 22, 42 and 52**, Garcia discloses a method wherein the querying comprises querying at least one database using the predefined criteria based on the identification of a pharmaceutical prescription to identify a series of targeted messages [column 4, lines 3-11]; and

wherein the playing comprises playing a succeeding one of the series of targeted messages to the caller in response to receipt of a caller response to a preceding one of the series of targeted messages [column 4, lines 3-11].

Regarding **claims 4, 23, 43, 63 and 77**, Garcia discloses a method further comprising: receiving a caller response to the targeted message [column 4, lines 3-11].

Regarding **claims 5**, **24 and 44**, Garcia discloses a method further comprising logging the caller response [column 4, lines 3-11].

Regarding **claims 6, 25, 26, 45, 46 and 66**, Garcia discloses a method further comprising instructing the pharmacy to perform an action in response to the caller response to the targeted message [column 4, lines 3-11].

Regarding **claims 8, 28, 67 and 81**, Garcia discloses a method wherein the predefined criteria based on the identification of a pharmaceutical prescription do not include a personal identification of a patient who is using the pharmaceutical prescription [column 3, lines 3-11].

Regarding **claims 11**, **3**, **71**, **80 and 51**, Garcia discloses a method wherein the querying comprises querying at least one database using the predefined criteria based on the identification of the pharmaceutical prescription to identify an educational targeted message concerning the pharmaceutical prescription [column 4, lines 3-11].

Regarding claims 12, 32, 52, 72 and 85, Garcia discloses a method wherein the querying comprises: querying at least one database using predefined criteria of last fill

Art Unit: 2614

date and days supply on last fill date based on the identification of a pharmaceutical prescription [column 4, lines 3-11]; and

identifying an educational targeted message that reminds the caller how to use the pharmaceutical prescription if the last fill date is less than a first threshold and the days supply on last fill date is greater than a second threshold [column 3, lines 3-11].

Regarding **claims 17**, **18**, **37**, **48**, **58** and **57**, Garcia discloses a method wherein the querying comprises: querying at least one pharmacy dispensing system database using the identification of the pharmaceutical prescription to identify the predetermined criteria [column 3, lines 28-43]; and

querying at least one message database using the predetermined criteria to identify a targeted message [column 3, lines 28-43].

Regarding **claims 19**, **39 and 59**, Garcia discloses a method wherein the identification of a pharmaceutical prescription is an Rx number [column 3, lines 28-43].

Regarding **claims 36**, **73 and 86**, Garcia discloses a method wherein the querying comprises: querying at least one database using predefined criteria of a patient who is using the pharmaceutical prescription that is based on the identification of a pharmaceutical prescription [column 3, lines 28-43]; and

identifying a targeted message that solicits participation of the patient in a study related to the pharmaceutical prescription if the age of the patient qualifies the patient to

Art Unit: 2614

participate in the study related to the pharmaceutical prescription [column 3, lines 28-43].

Regarding **claims 38, 46, 54**, Garcia discloses a method wherein the querying comprises: querying at least one pharmacy dispensing system database using the identification of the pharmaceutical prescription to identify the predetermined criteria [column 3, lines 28-43]; and

identifying at least one message database using the predetermined criteria to identify a targeted message [column 3, lines 28-43].

Allowable Subject Matter

- 6. Claims 50, 79, 97-101 and 109-111 are allowed.
- 7. Claims 47, 49, 53-56, 76, 78 and 82-84 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Art Unit: 2614

Response to Arguments

8. Applicant's arguments with respect to claims 1-9, 11-29, 31-49, 51-64, 66-78 and 80-111 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald Gauthier whose telephone number is (571) 272-7539. The examiner can normally be reached on 8:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Fan Tsang can be reached on (571) 272-7547. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 2614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Gerald Gauthier/ Primary Examiner, Art Unit 2614

/GG/ November 4, 2008